Portal de Periódicos da CAPES

Follow-up Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant

2015; Elsevier BV; Volume: 47; Issue: 1 Linguagem: Inglês

10.1016/j.transproceed.2014.11.021

1873-2623

Carolina Cuéllar‐García, C. Sevillano Ruiz-Mateos, María Auxiliadora Mazuecos Blanca, Carlos Narváez Mejía, Maikel Valle, Vicencia Martín Reina, Marina Bernal, M. Cobo, R. Rodriguez Lopez, C. de Cos Hohr, M.P. Garrastazul, I. Sanabria Marchante, Antonio Paz Coll, Francisco Javier Capote Huelva,

Amyloidosis: Diagnosis, Treatment, Outcomes

The aim of this work was to review the incidence of monoclonal gammopathy of undetermined significance (MGUS) and complications in kidney transplant (KT) patients at the Puerta del Mar Hospital in Cádiz, Spain. This diagnosis was not considered to be a contraindication for transplantation. To estimate the incidence of MGUS in KT patients we used the database of our hospital, which included 1,016 patients who received a KT from 1992 to 2012 with a median follow-up of 30 months. The incidence of MGUS in non-transplant patients was estimated from the literature. Out of 1,016 KT patients, 16 developed MGUS; 10 (72.5%) were >50 years old. Two patients developed post-transplantation lymphoproliferative disorders. No cases of progression to multiple myeloma or amyloidosis were seen during immune suppression therapy or after. MGUS was >100 times more frequent in KT recipients than in the general population (P < .05). But in contrast to MGUS in general population, progression to plasma cell dyscrasia in these patients was absent and its incidence is unknown in KT patients.